Bristol Myers Squibb announces positive results from Phase 3 Poetyk PsA-1 and PsA-2 trials of deucravacitinib in psoriatic arthritis

Bristol Myers Squibb announced positive results from the Phase 3 POETYK PSORIATIC ARTHRITIS-1 (PsA-1) and POETYK PSORIATIC ARTHRITIS-2 (PsA-2) trials evaluating Sotyktu (deucravacitinib), a selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in adults with active psoriatic arthritis (PsA).

The studies met their primary endpoints, with significantly more patients receiving Sotyktu achieving an American College of Rheumatology (ACR) 20 response at Week 16 versus placebo. Key secondary endpoints across skin and joint symptoms and health-related quality of life were also met.

Responses were maintained or improved through Week 52 in both studies. Safety results through Week 16 and Week 52 were consistent with the known profile of Sotyktu in plaque psoriasis and prior PsA studies.

The results were presented as late-breaking data at the European Congress of Rheumatology (EULAR 2025), held June 12-15 in Barcelona, Spain.

Sotyktu is the first oral selective TYK2 inhibitor approved for moderate to severe plaque psoriasis and is being evaluated for multiple immune-mediated diseases. TYK2 is a distinct member of the Janus kinase (JAK) family. Sotyktu selectively inhibits TYK2 via an allosteric mechanism by binding to the regulatory domain, without direct inhibition of JAK1/2/3.